arrow
M

Mari Nakamura

pennsylvania medicine
H指数:40
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:成人轻度至中度COVID-19的抗病毒治疗

2026-04-010
PRE
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:巴瑞替尼与托珠单抗

2026-04-010
PRE
The integrated stress response promotes immune evasion through lipocalin 2

整合应激反应通过脂质运载蛋白2促进免疫逃逸

Nature
IF48.5
2026-02-180
PRE
Establishing Priority Pediatric Antimicrobial Stewardship Interventions in the US: Findings from a Delphi Consensus Study

在美国建立儿科抗菌药物管理优先干预措施:一项德尔菲共识研究的结果

2025-10-110
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

2025年美国传染病学会关于COVID-19治疗和管理临床实践指南更新:Pemivibart用于暴露前预防,Vilobelimab用于危重疾病,Abatacept或Infliximab用于严重或危重疾病

2025-10-010
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:Abatacept

2025-09-010
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Infliximab

2025-08-011
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Vilobelimab

2025-07-011
OAAI
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

美国传染病学会关于新型冠状病毒肺炎管理的2024临床实践指南更新: Anti-SARS-CoV-2中和抗体Pemivibart用于暴露前预防

2024-10-291
PRE
Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

重症新型冠状病毒感染患儿的社区细菌合并感染

2023-03-065
OAAI
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
2023-01-189
OAAI
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19)
2022-09-05185
OA
Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children

美国儿童流感与冠状病毒疾病2019 (新型冠状病毒肺炎) 的危及生命的并发症

2022-07-1511
OA